Miyagoe-Suzuki Yuko, Takeda Shin'ichi
Yuko Miyagoe-Suzuki, Shin'ichi Takeda, Department of Molecular Therapy, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Kodaira, Tokyo 187-8502, Japan.
World J Stem Cells. 2017 Jun 26;9(6):89-97. doi: 10.4252/wjsc.v9.i6.89.
Human induced pluripotent stem cells (hiPS cells or hiPSCs) can be derived from cells of patients with severe muscle disease. If skeletal muscle induced from patient-iPSCs shows disease-specific phenotypes, it can be useful for studying the disease pathogenesis and for drug development. On the other hand, human iPSCs from healthy donors or hereditary muscle disease-iPSCs whose genomes are edited to express normal protein are expected to be a cell source for cell therapy. Several protocols for the derivation of skeletal muscle from human iPSCs have been reported to allow the development of efficient treatments for devastating muscle diseases. In 2017, the focus of research is shifting to another stage: (1) the establishment of mature myofibers that are suitable for study of the pathogenesis of muscle disease; (2) setting up a high-throughput drug screening system; and (3) the preparation of highly regenerative, non-oncogenic cells in large quantities for cell transplantation, .
人诱导多能干细胞(hiPS细胞或hiPSC)可从患有严重肌肉疾病的患者细胞中获得。如果由患者诱导多能干细胞诱导产生的骨骼肌表现出疾病特异性表型,那么它将有助于研究疾病发病机制以及药物研发。另一方面,来自健康供体的人诱导多能干细胞或基因组经编辑以表达正常蛋白质的遗传性肌肉疾病诱导多能干细胞有望成为细胞治疗的细胞来源。据报道,有几种从人诱导多能干细胞衍生骨骼肌的方案,可用于开发针对严重肌肉疾病的有效治疗方法。2017年,研究重点正转向另一个阶段:(1)建立适合研究肌肉疾病发病机制的成熟肌纤维;(2)建立高通量药物筛选系统;(3)大量制备用于细胞移植的高再生性、非致癌性细胞。